Psoriasis of the Nails

Mild-to-Moderate Psoriasis, Second Edition

Volumn , Issue , 2008, Pages 225-248

  Poindexter, Gabriele B ^a   Scher, Richard K ^a   Nendedkar Thomas, Maithily A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957966536     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14(3):485-496.
2. Rich P, Scher R. Nail Manifestations in Cutaneous Disease. An Atlas of Diseases of the Nail. Parthenon Publishing Group, Inc., 2003:51-54.
3. Elkayam O, Ophir J, Yaron M, et al. Psoriatic arthritis: Interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000; 19(4):301-305.
4. Brodell RT, Elewski B. Superficial fungal infections. Errors to avoid in diagnosis and treatment. Postgrad Med 1997; 101(4):279-287.
5. Schmults CA. Psoriasis confined to the nails. Dermatol Online J 2003; 9(4):7.
6. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1728 patients. Dermatology 1996; 193(4):300-303.
7. Fortune DG, Richards HL, Main CJ, et al. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998; 39(2, pt 1):196-201.
8. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: Development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41(2, pt 1):189-196.
9. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55(5):829-835.
10. Del-Rosso J, Basuk P, Scher R. Dermatologic disease of the nail unit. In: Scher RK, Daniel C, eds. Nails: Therapy, Diagnosis, Surgery, 2nd ed. Oxford, UK: Elsevier Saunders, 1997:172-200.
11. Zaias N. Psoriasis of the nail. A clinical-pathologic study. Arch Dermatol 1969; 99(5):567-579.
12. Tosti A, Piraccini BM. Biology of nails and nail disorders. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, eds. Fitzpatrick’s Dermatology in General Medicine, 7th ed. New York, NY: McGraw Hill, 2008:778-793.
13. Tham SN, Lim JJ, Tay SH, et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore 1988; 17(4):482-485.
14. Kaur I, Saraswat A, Kumar B. Nail changes in psoriasis: A study of 167 patients. Int J Dermatol 2001; 40(9):601-603.
15. Tosti A, Piraccini B. Dermatological diseases that affect the nail. In: Hordinsky M, Sawaya M, Scher R, eds. Atlas of Hair and Nails. Philadelphia, PA: Churchill Livingstone, 2000:47-49.
16. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57(1):1-27.
17. Scheinfeld NS. Trachyonychia: A case report and review of manifestations, associations, and treatments. Cutis 2003; 71(4):299-302.
18. Rich P. Nail disorders. Diagnosis and treatment of infectious, inflammatory, and neoplastic nail conditions. Med Clin North Am 1998; 82(5):1171-1183, vii.
19. Saladi RN, Persaud AN, Rudikoff D, et al. Idiopathic splinter hemorrhages. J Am Acad Dermatol 2004; 50(2):289-292.
20. Kouskoukis CE, Scher RK, Ackerman AB. The “oil drop” sign of psoriatic nails. A clinical finding specific for psoriasis. Am J Dermatopathol 1983; 5(3):259-262.
21. Scher RK. Psoriasis of the nail. Dermatol Clin 1985; 3(3):387-394.
22. Yerushalmi J, Grunwald MH, Hallel-Halevy D, et al. Chronic pustular eruption of the thumbs. Diagnosis: Acrodermatitis continua of Hallopeau (ACH). Arch Dermatol 2000; 136(7):925-930.
23. Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144(5):1000-1005.
24. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: A prospective clinical study. J Cutan Med Surg 2003; 7(4):317-321.
25. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3(1):55-78.
26. Ruzicka T. Psoriatic arthritis. New types, new treatments. Arch Dermatol 1996; 132(2):215-219.
27. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30(3):213-223.
28. Mease P, GoffeBS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52(1):1-19.
29. Winchester R. Psoriatic arthritis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, eds. Fitzpatrick’s Dermatology in General Medicine, 7th ed. New York, NY: McGraw Hill, 2008:194-207.
30. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33(9):834-839.
31. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999; 26(8):1752-1756.
32. Scarpa R, Manguso F, Oriente A, et al. Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis? Clin Rheumatol 2004; 23(1):27-30.
33. Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006; 33(7):1315-1319.
34. Serarslan G, Guler H, Karazincir S. The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis. Clin Rheumatol 2007; 26(8):1245-1247.
35. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: Nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43(6):790-794.
36. Gudjonsson JE, Karason A, Antonsdottir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118(2):362-365.
37. Henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997; 37(2 Pt 3):S1-S11.
38. Al-Mutairi N, Manchanda Y, Nour-Eldin O. Nail changes in childhood psoriasis: A study from Kuwait. Pediatr Dermatol 2007; 24(1):7-10.
39. al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol 1994; 11(2):116-119.
40. Watson W, Farber EM. Psoriasis in childhood. Pediatr Clin North Am 1971; 18(3):875-895.
41. Valdimarsson H, Baker BS, Jonsdottir I, et al. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16(3):145-149.
42. Kumar B, Jain R, Sandhu K, et al. Epidemiology of childhood psoriasis: A study of 419 patients from northern India. Int J Dermatol 2004; 43(9):654-658.
43. Nyfors A, Lemholt K. Psoriasis in children. A short review and a survey of 245 cases. Br J Dermatol 1975; 92(4):437-442.
44. Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: A clinical review of 1262 cases. Pediatr Dermatol 2001; 18(3):188-198.
45. Färber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica 1974; 148(1):1-18.
46. Melski JW, Stern RS. The separation of susceptibility to psoriasis from age at onset. J Invest Dermatol 1981; 77(6):474-477.
47. Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13(3):450-456.
48. Farber EM, Carlsen RA. Psoriasis in childhood. Calif Med 1966; 105(6):415-420.
49. Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res 2002; 294(5):207-213.
50. Duran-McKinster C, Ortiz-Solis D, Granados J, et al. Juvenile psoriatic arthritis with nail psoriasis in the absence of cutaneous lesions. Int J Dermatol 2000; 39(1):32-35.
51. Kacar N, Ergin S, Ergin C, et al. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: A prospective controlled trial. Clin Exp Dermatol 2007; 32(1):1-5.
52. Sanchez-Regana ML, Videla S, Villoria J, et al. Prevalence of fungal involvement in a series of patients with nail psoriasis. Clin Exp Dermatol 2008; 33(2):194-195.
53. Scher RK, Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br J Dermatol 2003; 149(suppl 65):5-9.
54. Staberg B, Gammeltoft M, Onsberg P. Onychomycosis in patients with psoriasis. Acta Derm Venereol 1983; 63(5):436-438.
55. Wilkinson DS. Dermatitis from repeated trauma to the skin. Am J Ind Med 1985; 8(4-5):307-317.
56. Hemmer W, Focke M, Wantke F, et al. Allergic contact dermatitis to artificial fingernails prepared from UV light-cured acrylates. J Am Acad Dermatol 1996; 35(3, pt 1):377-380.
57. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33(4):551-573; quiz 74-76.
58. Piraccini BM, Iorizzo M, Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol 2003; 4(1):31-37.
59. Robbins TO, Kouskoukis CE, Ackerman AB. Onycholysis in psoriatic nails. Am J Dermatopathol 1983; 5(1):39-41.
60. Leslie G. Linear psoriasis. Br J Dermatol 1951; 63(7):262-263.
61. Saraswat A, Sandhu K, Shukla R, et al. Unilateral linear psoriasis with palmoplantar, nail, and scalp involvement. Pediatr Dermatol 2004; 21(1):70-73.
62. Bondi EE. Psoriasis overlying an epidermal nevus. Arch Dermatol 1979; 115(5):624-625.
63. Sugai T, Shimotoge M, Saito T. Psoriasis and systematized epidermal nevus. Arch Dermatol 1970; 102(6):656-660.
64. de Jong E, Rulo HF, van de Kerkhof PC. Inflammatory linear verrucous epidermal naevus (ILVEN) versus linear psoriasis. A clinical, histological and immunohistochemical study. Acta Derm Venereol 1991; 71(4):343-346.
65. Tosti A, Peluso AM, Misciali C, et al. Nail lichen striatus: Clinical features and longterm follow-up of five patients. J Am Acad Dermatol 1997; 36(6, pt 1):908-913.
66. Baran R, Perrin C. Longitudinal erythronychia with distal subungual keratosis: Ony-chopapilloma of the nail bed and Bowen’s disease. Br J Dermatol 2000; 143(1):132-135.
67. Dobson CM, Azurdia RM, King CM. Squamous cell carcinoma arising in a psoriatic nail bed: Case report with discussion of diagnostic difficulties and therapeutic options. Br J Dermatol 2002; 147(1):144-149.
68. Tosti A, Morelli R, Fanti PA, et al. Carcinoma cuniculatum of the nail apparatus: Report of three cases. Dermatology 1993; 186(3):217-221.
69. Baran R, Dawber R, Deberker D, et al. Diseases of the nails and their management, 3rd ed. New York, NY: Blackwell Science, 2001.
70. Scher R, Daniel C. Nails: Therapy, Diagnosis, Surgery, 3rd ed. New York, NY: Elsevier Saunders, 2005.
71. Krull E, Zook E, Baran B, et al. Nail Surgery; A Text and Atlas. New York, NY: Lippincott Williams & Wilkins, 2000.
72. Grover C, Khandpur S, Reddy BS, et al. Longitudinal nail biopsy: Utility in 20-nail dystrophy. Dermatol Surg 2003; 29(11):1125-1129.
73. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49(2):206-212.
74. Kacar N, Ergin S, Erdogan BS. The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol 2008; 22(2):219-222.
75. Baran RL. A nail psoriasis severity index. Br J Dermatol 2004; 150(3):568-569.
76. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34(1):123-129.
77. Murdan S. 1st meeting on topical drug delivery to the nail. Expert Opin Drug Deliv 2007; 4(4):453-455.
78. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25(5):357-362.
79. Baran B, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatolog Treat 1999; 10(3):201-204.
80. Sanchez Regana M, Martin Ezquerra G, Umbert Millet P, et al. Treatment of nail psoriasis with 8% clobetasol nail lacquer: Positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005; 19(5):573-577.
81. Sanchez Regana M, Marquez Balbas G, Umbert Millet P. Nail psoriasis: A combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol 2008 Apr 10.
82. Wolf R, Tur E, Brenner S. Corticosteroid-induced ‘disappearing digit’. J Am Acad Dermatol 1990; 23(4, pt 1):755-756.
83. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139(4):655-659.
84. de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138(1):90-95.
85. Grover C, Bansal S, Nanda S, et al. Efficacy of triamcinolone acetonide in various acquired nail dystrophies. J Dermatol 2005; 32(12):963-968.
86. Khoo BP, Giam YC. A pilot study on the role of intralesional triamcinolone acetonide in the treatment of pitted nails in children. Singapore Med J 2000; 41(2):66-68.
87. Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123(5):571-572.
88. Zakeri M, Valikhani M, Mortazavi H, et al. Topical calcipotriol therapy in nail psoriasis: A study of 24 cases. Dermatol Online J 2005; 11(3):5.
89. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: Combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004; 8(2):122-125.
90. Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002; 82(2):140.
91. Goedkoop AY, de Rie MA, Picavet DI, et al. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004; 295(11):465-473.
92. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25(10):2487-2505.
93. Weinberg JM, Saini R, Tutrone WD. Biologic therapy for psoriasis—the first wave: Infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol 2002; 1(3):303-310.
94. Saripalli YV, Gaspari AA. Focus on: Biologics that affect therapeutic agents in dermatology. J Drugs Dermatol 2005; 4(2):233-245.
95. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49(2)(suppl):S44-S50.
96. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003; 49(2)(suppl):S105-S111.
97. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49(2)(suppl):S112-S117.
98. Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35(3):544-545.
99. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58(2):224-231.
100. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-850.
101. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9(1):1-14.
102. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49(2)(suppl):S87-S97.
103. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: A proof of concept study. J Drugs Dermatol 2006; 5(4):339-340.
104. Korver JE, Langewouters AM, Van De Kerkhof PC, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20(10):1252-1255.
105. Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol 2005; 52(6):1101-1102.
106. Leonardi CL. Efalizumab: An overview. J Am Acad Dermatol 2003; 49(2)(suppl):S98-S104.
107. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144(2):200-207.
108. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356(6):580-592.
109. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, inpatients with psoriasis: 76-weekre-sults from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371(9625):1665-1674.
110. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371(9625):1675-1684.
111. Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanony-chia striata, and onychomycosis. A review of the literature. Dermatol Clin 2000; 18(1):37-46.
112. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: A double-blind, randomized, vehicle-controlled study. Cutis 2001; 68(5):355-358.
113. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: An open, prospective study. Br J Dermatol 2003; 149(1):207-209.
114. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: A double-blind study. Acta Derm Venereol 2007; 87(2):167-168.
115. Roenigk RK, Gibstine C, Roenigk HH Jr.. Oral isotretinoin followed by psoralens and ultraviolet A or ultraviolet B for psoriasis. J Am Acad Dermatol 1985; 13(1):153-155.
116. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999; 41(3, pt 2):S22-S24.
117. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs. etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121(10):1297-1301.
118. Brazzelli V, Martinoli S, Prestinari F, et al. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 18(2):229-230.
119. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32(1):78-88.
120. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45(5):649-661; quiz 62-64.
121. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236(1-2):1-26.
122. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology 2003; 206(2):153-156.
123. Schissel DJ, Elston DM. Topical 5-fluorouracil treatment for psoriatic trachyonychia. Cutis 1998; 62(1):27-28.
124. Fredriksson T. Psoriatic nails and 5-fluorouracil. J Am Acad Dermatol 1982; 6(1):117.
125. de Jong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology 1999; 199(4):313-318.
126. Schmied E, Levy PM. Transient rhabdomyolysis connected with topical use of 5-fluorouracil in a patient with psoriasis of the nails. Dermatologica 1986; 173(5):257-258.
127. Gerster JC, Hohl D. Nail lesions in psoriatic arthritis: Recovery with sulfasalazine treatment. Ann Rheum Dis 2002; 61(3):277.
128. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25(4):231-233.
129. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116(9):1023-1024.
130. Yu RC, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol 1992; 72(2):134-136.
131. Aubin F, Vigan M, Puzenat E, et al. Evaluation of a novel 308-nm monochromatic ex-cimer light delivery system in dermatology: A pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152(1):99-103.
132. Lindelof B. Psoriasis of the nails treated with grenz rays: A double-blind bilateral trial. Acta Derm Venereol 1989; 69(1):80-82.